(ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR ...
BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a ...
Pyxis Oncology (PYXS) announced preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin, a first-in-concept ...
Pyxis Oncology, Inc. announced that the FDA has granted Fast Track Designation for its drug PYX-201, aimed at treating adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback